Invetx

Acquired by Dechra
Developing novel protein-based therapeutics for companion animals.
Developing novel protein-based therapeutics for companion animals.

Sector

Life Sciences

Category

Therapeutics

Location

Boston, MA

Initial Investment

2022
Invetx

Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. In July 2024, Invetx was acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business.

“F-Prime’s support has been instrumental in Invetx’s journey to become a leader in protein-based therapeutics for companion animals. Their deep understanding of the biotech landscape and their commitment to our vision have been invaluable.”
Jurgen Horn, CEO